Hypoxia and low-nutrition double stress induces aggressiveness in a murine model of melanoma

Cancer Science

Volumn 100, Issue 5, 2009, Pages 844-851

  Osawa, Tsuyoshi ^a   Muramatsu, Masashi ^a   Watanabe, Makoto ^b   Shibuya, Masabumi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER INVASION; CANCER RESISTANCE; CELL METABOLISM; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DISEASE MODEL; ENZYME REGULATION; FOOD DEPRIVATION; GENE EXPRESSION REGULATION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ADAPTATION, BIOLOGICAL; ANIMALS; CELL HYPOXIA; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; MELANOMA; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; STRESS, PHYSIOLOGICAL;

EID: 65349179595     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01105.x     Document Type: Article

References (41)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971; 285: 1182-6.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18: 4-25.
3. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol. 1995; 129: 895-8.
4. Risau W. Mechanisms of angiogenesis. Nature. 1997; 386: 671-4.
5. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25-35.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42.
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-50.
8. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34.
9. Kerbel RS, Yu J, Tran J et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001; 20: 79-86.
10. Glade BJ, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat. 2004; 7: 289-300.
11. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
12. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995; 270: 19761-6.
13. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006; 441: 437-43.
14. Das B, Yeger H, Tsuchida R et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 2005; 65: 7267-75.
15. Warburg O. On the origin of cancer cells. Science. 1956; 123: 309-14.
16. Takasu M, Tada Y, Wang JO, Tagawa M, Takenaga K. Resistance to apoptosis induced by microenvironmental stresses is correlated with metastatic potential in Lewis lung carcinoma. Clin Exp Metastasis. 1999; 17: 409-16.
17. Potier E, Ferreira E, Meunier A, Sedel L, Logeart-Avramoglou D, Petite H. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng. 2007; 13: 1325-31.
18. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82: 1107-12.
19. Yamauchi M, Imajoh-Ohmi S, Shibuya M. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci. 2007; 98: 1491-7.
20. Gotoh N, Ito M, Yamamoto S et al. Tyrosine phosphorylation sites on FRS2alpha responsible for Shp2 recruitment are critical for induction of lens and retina. Proc Natl Acad Sci USA. 2004; 101: 17144-9.
21. Morita S, Kojima T, Kitamura T. Plat-E, an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000; 7: 1063-6.
22. Toker A, Yoeli-Lerner M. Akt signaling and cancer: Surviving but not moving on. Cancer Res. 2006; 66: 3963-6.
23. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 1999; 100: 1423-31.
24. Folkman J. Endogenous angiogenesis inhibitors. APMIS. 2004; 112: 496-507.
25. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001; 7: 192-8.
26. Kopfstein L, Veikkola T, Djonov VG et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol. 2007; 170: 1348-61.
27. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410: 50-6.
28. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115: 1627-35.
29. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007; 129: 465-72.
30. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11: 69-82.
31. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005; 65: 9328-37.
32. Kawada K, Sonoshita M, Sakashita H et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004; 64: 4010-7.
33. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7: 763-77.
34. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4: 891-9.
35. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004; 20: 563-9.
36. Moore DD. Physiology. Sister act. Science. 2007; 316: 1436-8.
37. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J. 2008; 55: 23-31.
38. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 9-22.
39. Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells'tolerance to nutrient starvation. Cancer Sci. 2004; 95: 547-52.
40. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005; 16: 525-37.
41. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81.